

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **May 1, 2022** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the May 1, 2022 updates for complete listings of products available by special authorization, step therapy or special authorization, restricted benefits, added products, Least Cost Alternative (LCA) price changes, products with a price change and discontinued products.

Please note that the online Interactive Drug Benefit List (iDBL) at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application and, as such, contains the most up-to-date information.

Pan-Canadian Select Molecule Price Initiative for generic drugs

Alberta Drug Benefit List prices effective April 29, 2022

The Pan-Canadian Select Molecule Price Initiative, established in 2013 by the Health Care Innovation Working Group of the Council of the Federation, achieves better value for generic drugs by leveraging the combined purchasing power of participating jurisdictions to obtain the lowest generic prices achieved to date in Canada.

Effective **April 29, 2022**, the following generic molecules have been selected for additional price reductions: alendronate, atenolol, bisoprolol, carvedilol, dutasteride, finasteride, risedronate and risperidone.

Through a Pan-Canadian Price Confirmation process, manufacturers have confirmed their ability to supply the drugs included in this initiative at the below price points to pharmacies in participating provinces and territories, including Alberta.

Notification of prices is being provided at this time to allow pharmacies, manufacturers and wholesalers adequate time to adjust inventories and manage stock. The previous higher price will be recognized until May 31, 2022.

For more information on the Pan-Canadian Select Molecule Price Initiative, including the existing molecule list and price points, please visit pcpacanada.ca/generic-drug-framework.

continued next page

PHARMACY BENEFACT

continued from previous page

Please be advised that the April 29, 2022 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

The Pan-Canadian Select Molecule Price Initiative generic drug molecules with additional price reductions and the new price points are listed below:

pan-Canadian molecule	Price
ALENDRONATE SODIUM 70 MG TABLET	\$ 1.7804
ATENOLOL 25 MG TABLET	\$ 0.0441
ATENOLOL 50 MG TABLET	\$ 0.0938
ATENOLOL 100 MG TABLET	\$ 0.1543
BISOPROLOL FUMARATE 5 MG TABLET	\$ 0.0606
BISOPROLOL FUMARATE 10 MG TABLET	\$ 0.0885
CARVEDILOL 3.125 MG TABLET	\$ 0.2060
CARVEDILOL 6.25 MG TABLET	\$ 0.2060
CARVEDILOL 12.5 MG TABLET	\$ 0.2060
CARVEDILOL 25 MG TABLET	\$ 0.2060
DUTASTERIDE 0.5 MG CAPSULE	\$ 0.2565
FINASTERIDE 5 MG TABLET	\$ 0.3506
RISEDRONATE SODIUM 35 MG TABLET	\$ 1.6764
RISPERIDONE 0.25 MG TABLET	\$ 0.0878
RISPERIDONE 0.5 MG TABLET	\$ 0.1470
RISPERIDONE 1 MG TABLET	\$ 0.2031
RISPERIDONE 2 MG TABLET	\$ 0.4062
RISPERIDONE 3 MG TABLET	\$ 0.6083
RISPERIDONE 4 MG TABLET	\$ 0.8111

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

